SV2A protein is a broad-spectrum anticonvulsant target: Functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy

This publication has 32 references indexed in Scilit:

• Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy
  Neurology, 2007
• Synaptic Vesicle Protein 2 Enhances Release Probability at Quiescent Synapses
  The Journal of Neuroscience, 2006
• Effects of levetiracetam on spike and wave discharges in WAG/Rij rats
  Seizure: European Journal of Epilepsy, 2004
• Sensitivity of thalamic GABAergic currents to clonazepam does not differ between control and genetic absence epilepsy rats
  Brain Research, 2004
• Binding characteristics of [3H]ucb 30889 to levetiracetam binding sites in rat brain
  European Journal of Pharmacology, 2003
• Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)
  Proceedings of the National Academy of Sciences, 1999
• Gabapentin potentiates the antiseizure activity of certain anticonvulsants in DBA/2 mice
  European Journal of Pharmacology, 1998
• Felbamate and meprobamate: a comparison of their anticonvulsant properties
  Epilepsy Research, 1997
• Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy
  Epilepsy Research, 1995
• Effects of the GABA-uptake inhibitor tiagabine on electroencephalogram, spike-wave discharges and behaviour of rats
  Epilepsy Research, 1995